Overview

How does your management of patients with migraine compare to the experts? By participating in this six-part educational initiative, which incorporates a comprehensive roundtable faculty discussion, augmented reality, and a patient narrative, you will be able to incorporate key information into your clinical practice immediately.

Learning Objectives

  • Incorporate best practices for the differential diagnosis of migraine headaches
  • Assess efficacy and safety profiles of agents prescribed for the treatment of migraine, including calcitonin-gene related peptide (CGRP) targeting agents for the prevention (prophylactic treatment) of episodic and chronic migraine
  • Individualize treatment plans for patients who suffer from acute and chronic migraines including goals for prevention and improved quality of life

Faculty

 

Dawn C. Buse

Clinical Professor, Department of Neurology
Albert Einstein College of Medicine of Yeshiva University, New York City
Role: Chair/Speaker

Linda Davis

Family Medicine
Kolvita Family Medical Group, Mission Viejo, CA (Organization/Company)
Role: Faculty/Speaker

Jack Schim, MD

Co-Director, The Headache Center of Southern California
The Neurology Center (Organization/Company)
Role: Faculty/Speaker

Faculty Financial Disclosures

All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any commercial financial affiliations with ineligible entities related to the content of the presentation or enduring material. Full disclosure must be made in writing to the audience prior to the activity.

All additional planning committee members, staff, and reviewers of Simumetrix and Purdue University College of Pharmacy have no relationships to disclose. The faculty reported the following financial relationships or relationships to products or devices they have with ineligible entities related to the content of this CME activity:

Dawn C. Buse, PhD has disclosed the following: receiving grant/research support Amgen, National Headache Foundation, and the FDA; serves as a consultant for Amgen, Allergan/AbbVie, Lilly, Lundbeck, and Teva; is a member of the Advisory Board for Allergan/AbbVie, Lilly, Lundbeck, and Teva; and is involved with the Editorial Board for Current Pain and Headache Reports.

Linda Davis, MD has disclosed the following: consulting for Lilly, Amgen/Novartis, AbbVie; is a member of the Speakers Bureau for Lilly; and is a member of the Advisory Board for Lilly, Amgen/Novartis, and AbbVie.

Jack Schim, MD has disclosed the following: receiving grant/research support from Alder, Allergan, Amgen, electroCore, Lilly, Teva, Theranica; serving as a consultant for Aeon, Alder, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, and Lundbeck; is a member of the Speakers Bureau for AbbVie. Alder, Allergan, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Teva, Theranica, and Upsher-Smith; is a member of the Advisory Board for Aeon, Alder, Allergan, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, Lundbeck, Novartis, Revance, Teva, Theranica, and Upsher-Smith; and has received non-CE related honorarium from AbbVie, Alder, Allergan, Biohaven, electroCore, Lilly, Lundbeck, Novartis, and Teva.

These relationships have been reviewed and mitigated through peer-review of content by individual without relevant financial relationship.

CME Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Simumetrix. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.


Designation Statement

Purdue University College of Pharmacy designates this internet enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 7 out of the 11 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Commercial Supporter

Lilly USA, LLC and Lundbeck LLC

Education Partner

Simumetrix


Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.